{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T03:50:12Z","timestamp":1768881012841,"version":"3.49.0"},"reference-count":8,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2011,10,13]],"date-time":"2011-10-13T00:00:00Z","timestamp":1318464000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Dermatology"],"published-print":{"date-parts":[[2012,7]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold> Although anti\u2010tumor necrosis factor alpha (TNF\u2010\u03b1) agents are commonly used to treat psoriasis and other inflammatory diseases in adults and children, numerous reports have documented new\u2010onset or flaring psoriasis in adults treated for the other conditions. Individual case reports have documented similar observations in three children. We report a series of anti\u2010TNF\u2010\u03b1\u2010induced psoriasis in children with juvenile idiopathic arthritis or inflammatory bowel disease treated at a large children\u2019s hospital. All five patients presented with severe scalp involvement. One child was treated with adalimumab for juvenile idiopathic arthritis, and four received infliximab for inflammatory bowel disease. The five patients developed psoriasis 2 to 10\u2003months after initiating anti\u2010TNF\u2010\u03b1 therapy. They presented with erythematous, scaly, crusted scalp lesions. Three of the five patients were initially treated with griseofulvin for presumed tinea capitis. The anti\u2010TNF\u2010\u03b1 agent was discontinued at the time of diagnosis in two cases. Topical steroids were the mainstay of psoriasis therapy, with improvement in four of five patients. Anti\u2010TNF\u2010\u03b1 agents have been associated with the onset or worsening of psoriasis in adults, but this has rarely been reported in children. We describe five pediatric cases of anti\u2010TNF\u2010\u03b1\u2010induced psoriasis presenting with severe scalp involvement and review their subsequent management. We hope that clinicians caring for patients receiving anti\u2010TNF\u2010\u03b1 agents will consider psoriasis from the onset of cutaneous symptoms and institute appropriate therapy or referral.<\/jats:p>","DOI":"10.1111\/j.1525-1470.2011.01521.x","type":"journal-article","created":{"date-parts":[[2011,10,13]],"date-time":"2011-10-13T12:29:40Z","timestamp":1318508980000},"page":"454-459","source":"Crossref","is-referenced-by-count":43,"title":["Five Cases of Anti\u2010Tumor Necrosis Factor Alpha\u2013Induced Psoriasis Presenting with Severe Scalp Involvement in Children"],"prefix":"10.1111","volume":"29","author":[{"given":"Marissa J.","family":"Perman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Lovell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee A.","family":"Denson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael K.","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne W.","family":"Lucky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,10,13]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"380","article-title":"Psoriasis induced by tumor necrosis factor\u2010alpha antagonist therapy: a case series","volume":"34","author":"Cohen JD","year":"2007","journal-title":"J Rheumatol"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20954"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200809010-00001"},{"key":"e_1_2_5_5_2","unstructured":"Information for healthcare professionals: tumor necrosis factor (TNF) blockers(marketed as Remicade Enbrel Humira Cimzia and Simponi) http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/ucm174474.htm. Accessed on August 24 2010."},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anpedi.2008.11.013"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.049916"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2010.01267.x"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546630802441234"}],"container-title":["Pediatric Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1525-1470.2011.01521.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1525-1470.2011.01521.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T06:17:28Z","timestamp":1698646648000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1525-1470.2011.01521.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,13]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["10.1111\/j.1525-1470.2011.01521.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1525-1470.2011.01521.x","archive":["Portico"],"relation":{},"ISSN":["0736-8046","1525-1470"],"issn-type":[{"value":"0736-8046","type":"print"},{"value":"1525-1470","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,13]]}}}